HRP20211386T1 - Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate - Google Patents
Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate Download PDFInfo
- Publication number
- HRP20211386T1 HRP20211386T1 HRP20211386TT HRP20211386T HRP20211386T1 HR P20211386 T1 HRP20211386 T1 HR P20211386T1 HR P20211386T T HRP20211386T T HR P20211386TT HR P20211386 T HRP20211386 T HR P20211386T HR P20211386 T1 HRP20211386 T1 HR P20211386T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- group
- cells
- tumors
- compound
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title claims 10
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title claims 10
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 27
- -1 p-methoxybenzyl Chemical group 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000002738 chelating agent Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 6
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 6
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 208000023958 prostate neoplasm Diseases 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 150000003536 tetrazoles Chemical class 0.000 claims 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000028591 pheochromocytoma Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Spoj formule (I):
[image]
naznačen time da:
Z je tetrazol ili CO2Q;
Q je H ili zaštitna grupa, pri čemu je zaštitna grupa odabrana iz grupe koja se sastoji od benzila, p-metoksibenzila (PMB), tercijarnog butila (t-Bu), metoksimetila (MOM), metoksietoksimetila (MEM), metiltiometila (MTM), tetrahidropiranila (THP), tetrahidrofuranila (THF), benziloksimetila (BOM), trimetilsilila (TMS), trietilsilila (TES), t-butildimetilsilila (TBDMS), i trifenilmetila (tritil, Tr);
m je cijeli broj odabran iz grupe koja se sastoji od 1, 2, 3, 4, i 5;
R je -CH2-R1;
R1 je odabran iz grupe koja se sastoji od:
[image]
pri čemu je X neovisno Br ili I;
L je veznik odabran iz grupe koja se sastoji od C1-C6 alkilena i C3-C6 cikloalkilena, i arilena;
W je odabran iz grupe koja se sastoji od -NR2-(C=O)-, -NR2-(C=S)-, -(C=O)-NR2-, i -(C=S)-NR2-; pri čemu u svakom pojavljivanju L i W može biti isti ili različit;
R2 je H ili C1-C4 alkil;
n je cijeli broj odabran iz grupe koja se sastoji od 1, 2, i 3; i
Ch je kelatno sredstvo koje sadrži radiometal odabran iz grupe koja se sastoji od 68Ga, 64Cu, 86Y, 90Y, 89Zr, 111In, 99mTc, 177Lu, 153Sm, 186Re, 188Re, 67Cu, 212Pb, 225Ac, 213Bi, 212Bi, 212Pb, 67Ga, 203Pb, 47Sc, i 166Ho, pri čemu je kelatno sredstvo odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
i njegovih farmaceutski prihvatljivih soli.
2. Spoj prema patentnom zahtjevu 1, naznačen time da je spoj formule (I) odabran iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
3. Spoj formule (I) za uporabu u liječenju jednog ili više tumora ili stanica koje eksprimiraju membranski antigen specifičan za prostatu (PSMA), naznačen time da spoj formule (I) sadrži:
[image]
pri čemu:
Z je tetrazol ili CO2Q;
Q je H ili zaštitna grupa, pri čemu je zaštitna grupa odabrana iz grupe koja se sastoji od benzila, p-metoksibenzila (PMB), tercijarnog butila (t-Bu), metoksimetila (MOM), metoksietoksimetila (MEM), metiltiometila (MTM), tetrahidropiranila (THP), tetrahidrofuranila (THF), benziloksimetila (BOM), trimetilsilila (TMS), trietilsilila (TES), t-butildimetilsilila (TBDMS), i trifenilmetila (tritil, Tr);
m je cijeli broj odabran iz grupe koja se sastoji od 1, 2, 3, 4, i 5;
R je -CH2-R1;
R1 je odabran iz grupe koja se sastoji od:
[image]
pri čemu je X neovisno Br ili I;
L je veznik odabran iz grupe koja se sastoji od C1-C6 alkilena i C3-C6 cikloalkilena, i arilena;
W je odabran iz grupe koja se sastoji od -NR2-(C=O)-, -NR2-(C=S)-, -(C=O)-NR2-, i -(C=S)-NR2-; pri čemu u svakom pojavljivanju L i W može biti isti ili različit;
R2 je H ili C1-C4 alkil;
n je cijeli broj odabran iz grupe koja se sastoji od 1, 2, i 3; i
Ch je kelatno sredstvo koje sadrži radiometal odabran iz grupe koja se sastoji od 68Ga, 64Cu, 86Y, 90Y, 89Zr, 111In, 99mTc, 177Lu, 153Sm, 186Re, 188Re, 67Cu, 212Pb, 225Ac, 213Bi, 212Bi, 212Pb, 67Ga, 203Pb, 47Sc, i 166Ho, pri čemu je kelatno sredstvo odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
i njihovih farmaceutski prihvatljivih soli.
4. Spoj za uporabu prema patentnom zahtjevu 3, naznačen time da je spoj odabran iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
5. Spoj za uporabu prema patentnom zahtjevu 3 ili patentnom zahtjevu 4, naznačen time da je jedan ili više tumora ili stanica koje eksprimiraju PSMA odabran iz grupe koja se sastoji od: tumora ili stanica prostate, metastaziranog tumora ili stanica prostate, tumora ili stanica pluća, tumora ili stanica bubrega, glioblastoma, tumora ili stanica gušterače, tumora ili stanica mjehura, sarkoma, melanoma, tumora ili stanica dojke, tumora ili stanica debelog crijeva, germinativnih stanica, feokromocitoma, tumora ili stanica jednjaka, tumora ili stanica želuca, i njihovih kombinacija.
6. Spoj za uporabu prema patentnom zahtjevu 3 ili patentnom zahtjevu 4, naznačen time da jedan ili više tumora ili stanica koje eksprimiraju PSMA su tumor ili stanice prostate.
7. Spoj za uporabu prema patentnom zahtjevu 3 ili patentnom zahtjevu 4, naznačen time da liječenje rezultira u inhibiciji rasta tumora.
8. Postupak za liječenje jednog ili više tumora ili stanica koje eksprimiraju membranski antigen specifičan za prostatu (PSMA) in vitro ili ex vivo, naznačen time da postupak sadrži kontaktiranje jednog ili više in vitro ili ex vivo tumora ili stanica koje eksprimiraju PSMA sa efikasnom količinom spoja formule (I), pri čemu spoj formule (I) sadrži:
[image]
pri čemu:
Z je tetrazol ili CO2Q;
Q je H ili zaštitna grupa, pri čemu je zaštitna grupa odabrana iz grupe koja se sastoji od benzila, p-metoksibenzial (PMB), tercijarnog butila (t-Bu), metoksimetila (MOM), metoksietoksimetila (MEM), metiltiometila (MTM), tetrahidropiranila (THP), tetrahidrofuranila (THF), benziloksimetila (BOM), trimetilsilila (TMS), trietilsilila (TES), t-butildimetilsilila (TBDMS), i trifenilmetila (tritil, Tr);
m je cijeli broj odabran iz grupe koja se sastoji od 1, 2, 3, 4, i 5;
R je -CH2-R1;
R1 je odabran iz grupe koja se sastoji od:
[image]
pri čemu je X neovisno Br ili I;
L je veznik odabran iz grupe koja se sastoji od C1-C6 alkilena i C3-C6 cikloalkilena, i arilena;
W je odabran iz grupe koja se sastoji od -NR2-(C=O)-, -NR2-(C=S)-, -(C=O)-NR2-, i -(C=S)-NR2-; pri čemu u svakom pojavljivanju L i W može biti isti ili različit;
R2 je H ili C1-C4 alkil;
n je cijeli broj odabran iz grupe koja se sastoji od 1, 2, i 3; i
Ch je kelatno sredstvo koje sadrži radiometal odabran iz grupe koja se sastoji od 68Ga, 64Cu, 86Y, 90Y, 89Zr, 111In, 99mTc, 177Lu, 153Sm, 186Re, 188Re, 67Cu, 212Pb, 225Ac, 213Bi, 212Bi, 212Pb, 67Ga, 203Pb, 47Sc, i 166Ho, pri čemu je kelatno sredstvo odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
i njihovih farmaceutski prihvatljivih soli.
9. Postupak prema patentnom zahtjevu 8, naznačen time da je spoj odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
10. Postupak prema patentnom zahtjevu 8, naznačen time da je jedan ili više tumora ili stanica koje eksprimiraju PSMA odabrano iz grupe koja se sastoji od: tumora ili stanica prostate, metastaziranog tumora ili stanica prostate, tumora ili stanica pluća, tumora ili stanica bubrega, glioblastoma, tumora ili stanica gušterače, tumora ili stanica mjehura, sarkoma, melanoma, tumora ili stanica dojke, tumora ili stanica debelog crijeva, germinativnih stanica, feokromocitoma, tumora ili stanica jednjaka, tumora ili stanica želuca, i njihovih kombinacija.
11. Postupak prema patentnom zahtjevu 8, naznačen time da jedan ili više tumora ili stanica koje eksprimiraju PSMA su tumor ili stanice prostate.
12. Postupak prema patentnom zahtjevu 8, naznačen time da liječenje rezultira u inhibiciji rasta tumora.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| EP17771028.2A EP3433238B1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211386T1 true HRP20211386T1 (hr) | 2021-12-10 |
Family
ID=59899817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240215TT HRP20240215T1 (hr) | 2016-03-22 | 2017-03-22 | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
| HRP20211386TT HRP20211386T1 (hr) | 2016-03-22 | 2021-08-31 | Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240215TT HRP20240215T1 (hr) | 2016-03-22 | 2017-03-22 | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11458213B2 (hr) |
| EP (3) | EP3925952B1 (hr) |
| JP (3) | JP7073270B2 (hr) |
| KR (3) | KR20220063298A (hr) |
| CN (2) | CN109311827B (hr) |
| AU (1) | AU2017238181B2 (hr) |
| BR (1) | BR112018069507A2 (hr) |
| CA (1) | CA3018709A1 (hr) |
| CL (1) | CL2018002683A1 (hr) |
| CY (1) | CY1124487T1 (hr) |
| DK (2) | DK3433238T3 (hr) |
| ES (2) | ES2972148T3 (hr) |
| FI (1) | FI3925952T3 (hr) |
| HR (2) | HRP20240215T1 (hr) |
| HU (2) | HUE055607T2 (hr) |
| LT (2) | LT3925952T (hr) |
| MX (1) | MX2018011519A (hr) |
| PH (1) | PH12018502048A1 (hr) |
| PL (2) | PL3925952T3 (hr) |
| PT (2) | PT3433238T (hr) |
| RS (2) | RS62274B1 (hr) |
| RU (2) | RU2021115958A (hr) |
| SA (1) | SA518400103B1 (hr) |
| SI (2) | SI3433238T1 (hr) |
| TR (1) | TR201813644T1 (hr) |
| WO (1) | WO2017165473A1 (hr) |
| ZA (1) | ZA201806389B (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3030907A1 (en) | 2016-08-10 | 2018-02-15 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
| WO2018098390A1 (en) * | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
| WO2018111989A1 (en) | 2016-12-14 | 2018-06-21 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| US11491247B2 (en) | 2017-05-02 | 2022-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| US11478558B2 (en) | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| RS63279B1 (sr) * | 2017-12-11 | 2022-06-30 | Univ Muenchen Tech | Psma ligandi za snimanje i endoradioterapiju |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| US10377778B2 (en) * | 2017-12-13 | 2019-08-13 | Sciencons AS | Lead and thorium compounds |
| JP2021512949A (ja) * | 2018-02-06 | 2021-05-20 | ウニベルジテート ハイデルベルク | Ｆａｐ阻害物質 |
| CN112020497A (zh) * | 2018-02-06 | 2020-12-01 | 约翰霍普金斯大学 | 用于癌症放射治疗的psma靶向的放射性卤化尿素-聚氨基羧酸盐 |
| KR102156385B1 (ko) * | 2018-03-30 | 2020-09-15 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| WO2019240884A2 (en) * | 2018-04-27 | 2019-12-19 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| WO2020065045A1 (en) * | 2018-09-28 | 2020-04-02 | Universität Heidelberg | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| CN114096526A (zh) * | 2019-07-02 | 2022-02-25 | 诺华股份有限公司 | 前列腺特异性膜抗原（psma）配体及其用途 |
| AU2020299974A1 (en) | 2019-07-02 | 2022-01-27 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (PSMA) ligands and uses thereof |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| AU2021262479A1 (en) | 2020-04-29 | 2022-11-17 | Novartis Ag | Methods for radiolabelling PSMA binding ligands and their kits |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| WO2022106633A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| EP4355376A1 (en) * | 2021-06-17 | 2024-04-24 | Mayo Foundation for Medical Education and Research | Methods and materials for combining biologics with multiple chelators |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| WO2023152671A1 (en) | 2022-02-09 | 2023-08-17 | Novartis Ag | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101784192B (zh) | 2007-06-26 | 2015-03-18 | 约翰·霍普金斯大学 | 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| AU2009322167B2 (en) * | 2008-12-05 | 2014-11-20 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA |
| HRP20221195T1 (hr) * | 2009-03-19 | 2022-12-09 | The Johns Hopkins University | Spojevi koji ciljaju psma i njihova uporaba |
| JP5843338B2 (ja) | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| CN113149921A (zh) * | 2011-11-30 | 2021-07-23 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| CN105025933B (zh) * | 2013-01-14 | 2019-03-26 | 分子制药洞察公司 | 三嗪类放射性药物和放射性显影剂 |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| RS65324B1 (sr) * | 2013-10-18 | 2024-04-30 | Novartis Ag | Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate |
| US10683272B2 (en) * | 2014-05-06 | 2020-06-16 | The Johns Hopkins University | Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy |
| WO2016030329A1 (en) | 2014-08-24 | 2016-03-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| WO2016065435A2 (en) * | 2014-10-30 | 2016-05-06 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en active Application Filing
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Application Discontinuation
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 BR BR112018069507A patent/BR112018069507A2/pt unknown
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active IP Right Grant
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 MX MX2018011519A patent/MX2018011519A/es unknown
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Application Discontinuation
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 CN CN202210306552.XA patent/CN114716387A/zh active Pending
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
-
2021
- 2021-08-31 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211386T1 (hr) | Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate | |
| JP2019519467A5 (hr) | ||
| HRP20160164T1 (hr) | Citotoksiäśni derivati benzodiazepina | |
| WO2008041053A3 (en) | Inhibitors of vegf receptor and hgf receptor signaling | |
| ATE269357T1 (de) | Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf | |
| IL266563B (en) | Heterocyclic compounds used as pdk1 inhibitors | |
| JP2019522660A (ja) | ピロロベンゾジアゼピンおよびその結合体 | |
| NZ701478A (en) | Pyrrolobenzodiazepines | |
| NZ701290A (en) | Pyrrolobenzodiazepines | |
| CA3115725A1 (en) | Hybrid imaging agents for prostate-specific membrane antigen | |
| JP2012516896A5 (hr) | ||
| SI2079486T1 (en) | Effective synthesis of chelators for nuclear imaging and radiotherapy: composition and use | |
| MY159257A (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| MA31324B1 (fr) | Composés contenant de l'azote tricyclique utilisés en tant qu'agents antibactériens | |
| WO2006044826A3 (en) | Thiophens and their use as anti-tumor agents | |
| JP2020502271A5 (hr) | ||
| AU2016237099C1 (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
| AU2017237186A1 (en) | Process for the preparation of PEGylated drug-linkers and intermediates thereof | |
| JP2011505371A5 (hr) | ||
| NO20074360L (no) | Behandling av metastaterte tumorer | |
| CA2961935C (en) | Nitrogen-containing compound or salt thereof, or metal complex thereof | |
| CA3100319A1 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| WO2013181697A1 (en) | Bicyclo[6.1.0]non-4-yne compounds suitable for use as linkers in biological applications | |
| EA201000656A1 (ru) | Аминопроизводные 1,2,4-триазола в качестве модуляторов mglur5 | |
| JP2021505542A (ja) | 薬物リンカー化合物の調製のためのプロセス |